Matches in SemOpenAlex for { <https://semopenalex.org/work/W1980485091> ?p ?o ?g. }
- W1980485091 endingPage "53" @default.
- W1980485091 startingPage "40" @default.
- W1980485091 abstract "Pyridostigmine bromide, a reversible cholinesterase inhibitor, was administered orally (capsule gavage) to beagle dogs (10–15 months of age) of both sexes once daily at 5, 10, or 20 mg/kg for 14 days; every 8 hr at 2 or 5 mg/kg for 28 days; or every 8 hr at 0.05, 0.5, or 2 mg/kg for 3 months as part of its preclinical safety assessment. A small portion of the dogs receiving pyridostigmine for 3 months were allowed an untreated recovery period of an additional 3 months. Daily doses of 10 or 20 mg/kg were lethal to some of the dogs when given for up to 14 days and caused severe intestinal distress, including diarrhea, emesis, and reddened feces in all animals. The cause of death was intestinal intussusception. Signs of systemic toxicity apparent at these doses included hypersalivation and tremors. Similar but less severe effects were produced by 5 mg/kg per day; plasma cholinesterase activities were inhibited by all three doses in a dose-related manner. Signs of toxicity in the 28-day and 3-month studies were generally limited to the gastrointestinal tract and included diarrhea or soft stools and reddened or mucoid-containing stools; these signs appeared to reverse upon discontinuation of the drug. A single dog at 2 mg/kg every 8 hr developed an apparent intussusception. There were no pathological changes in clinical chemistry, hematology, or urinalysis parameters associated with doses of 0.05, 0.5, or 2 mg/kg every 8 hr for up to 3 months, nor were any drug-related lesions observed upon gross necropsy and microscopic evaluation of the major tissues and organs. Red blood cell (RBC) acetylcholinesterase (AChE) activities in the 3-month study were inhibited by approximately 10, 50, and 70% in the 0.05, 0.5, and 2 mg/kg every 8-hr dose groups, respectively, and these degrees of inhibition were maintained throughout the period of treatment. These data suggest that prolonged oral administration of pyridostigmine at doses sufficient to cause profound and sustained inhibition of RBC AChE activity (i.e., as high as 70%) cause mainly local, gastrointestinal distress related to altered intestinal motility. At the extreme, this can be manifested as a life-threatening intestinal intussusception. Systemic anticholinesterase effects (other than enzyme inhibition) were observed only at doses of 2 mg/kg and greater, while local (gastrointestinal) effects and inhibition of RBC AChE were observed at doses as low as 0.05 mg/kg." @default.
- W1980485091 created "2016-06-24" @default.
- W1980485091 creator A5034594558 @default.
- W1980485091 creator A5046687415 @default.
- W1980485091 creator A5053466244 @default.
- W1980485091 creator A5062889758 @default.
- W1980485091 creator A5079764722 @default.
- W1980485091 date "1990-01-01" @default.
- W1980485091 modified "2023-09-27" @default.
- W1980485091 title "Pharmacological and toxicological evaluation of orally administered pyridostigmine in dogs*1" @default.
- W1980485091 cites W1964436235 @default.
- W1980485091 cites W1971048984 @default.
- W1980485091 cites W1982702984 @default.
- W1980485091 cites W1983980105 @default.
- W1980485091 cites W1997988401 @default.
- W1980485091 cites W2029138361 @default.
- W1980485091 cites W2040399114 @default.
- W1980485091 cites W2045791927 @default.
- W1980485091 cites W2048411785 @default.
- W1980485091 cites W2064433369 @default.
- W1980485091 cites W2069192830 @default.
- W1980485091 cites W2070009582 @default.
- W1980485091 cites W2074026543 @default.
- W1980485091 cites W2094667525 @default.
- W1980485091 cites W2095461199 @default.
- W1980485091 cites W2098264812 @default.
- W1980485091 cites W2109668811 @default.
- W1980485091 cites W2111524191 @default.
- W1980485091 cites W2122180277 @default.
- W1980485091 cites W2125751048 @default.
- W1980485091 cites W2315380771 @default.
- W1980485091 cites W2407016060 @default.
- W1980485091 cites W2941732570 @default.
- W1980485091 cites W3112457990 @default.
- W1980485091 doi "https://doi.org/10.1016/0272-0590(90)90229-d" @default.
- W1980485091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2307321" @default.
- W1980485091 hasPublicationYear "1990" @default.
- W1980485091 type Work @default.
- W1980485091 sameAs 1980485091 @default.
- W1980485091 citedByCount "29" @default.
- W1980485091 countsByYear W19804850912012 @default.
- W1980485091 countsByYear W19804850912013 @default.
- W1980485091 countsByYear W19804850912014 @default.
- W1980485091 countsByYear W19804850912016 @default.
- W1980485091 countsByYear W19804850912019 @default.
- W1980485091 countsByYear W19804850912020 @default.
- W1980485091 countsByYear W19804850912022 @default.
- W1980485091 crossrefType "journal-article" @default.
- W1980485091 hasAuthorship W1980485091A5034594558 @default.
- W1980485091 hasAuthorship W1980485091A5046687415 @default.
- W1980485091 hasAuthorship W1980485091A5053466244 @default.
- W1980485091 hasAuthorship W1980485091A5062889758 @default.
- W1980485091 hasAuthorship W1980485091A5079764722 @default.
- W1980485091 hasConcept C126322002 @default.
- W1980485091 hasConcept C2776820430 @default.
- W1980485091 hasConcept C2778105408 @default.
- W1980485091 hasConcept C2778715236 @default.
- W1980485091 hasConcept C2779225474 @default.
- W1980485091 hasConcept C2779802037 @default.
- W1980485091 hasConcept C2779901103 @default.
- W1980485091 hasConcept C2779998641 @default.
- W1980485091 hasConcept C2780026642 @default.
- W1980485091 hasConcept C2910532367 @default.
- W1980485091 hasConcept C29730261 @default.
- W1980485091 hasConcept C31896038 @default.
- W1980485091 hasConcept C42219234 @default.
- W1980485091 hasConcept C42407357 @default.
- W1980485091 hasConcept C71924100 @default.
- W1980485091 hasConcept C90924648 @default.
- W1980485091 hasConcept C98274493 @default.
- W1980485091 hasConceptScore W1980485091C126322002 @default.
- W1980485091 hasConceptScore W1980485091C2776820430 @default.
- W1980485091 hasConceptScore W1980485091C2778105408 @default.
- W1980485091 hasConceptScore W1980485091C2778715236 @default.
- W1980485091 hasConceptScore W1980485091C2779225474 @default.
- W1980485091 hasConceptScore W1980485091C2779802037 @default.
- W1980485091 hasConceptScore W1980485091C2779901103 @default.
- W1980485091 hasConceptScore W1980485091C2779998641 @default.
- W1980485091 hasConceptScore W1980485091C2780026642 @default.
- W1980485091 hasConceptScore W1980485091C2910532367 @default.
- W1980485091 hasConceptScore W1980485091C29730261 @default.
- W1980485091 hasConceptScore W1980485091C31896038 @default.
- W1980485091 hasConceptScore W1980485091C42219234 @default.
- W1980485091 hasConceptScore W1980485091C42407357 @default.
- W1980485091 hasConceptScore W1980485091C71924100 @default.
- W1980485091 hasConceptScore W1980485091C90924648 @default.
- W1980485091 hasConceptScore W1980485091C98274493 @default.
- W1980485091 hasIssue "1" @default.
- W1980485091 hasLocation W19804850911 @default.
- W1980485091 hasLocation W19804850912 @default.
- W1980485091 hasOpenAccess W1980485091 @default.
- W1980485091 hasPrimaryLocation W19804850911 @default.
- W1980485091 hasRelatedWork W1953960087 @default.
- W1980485091 hasRelatedWork W1976955739 @default.
- W1980485091 hasRelatedWork W1980485091 @default.
- W1980485091 hasRelatedWork W2040932827 @default.
- W1980485091 hasRelatedWork W2082897244 @default.
- W1980485091 hasRelatedWork W2145696702 @default.